IPO
South San Francisco-based RAPT Therapeutics announced it is postponing its initial public offering (IPO) it filed earlier to raise $86 million via selling 5 million shares at $14 to $16 per share. No reasons were given for the postponement.
Ultragenyx Pharmaceutical Inc. reported its financial results and corporate update for the quarter ended June 30, 2019.
Great Bay Bio, a leading biotechnology company dedicated to innovative biologics CMC (Chemistry Manufacturing and Controls) and development of biologics development big data platform, the board is pleased to announce the introduction of a new non-executive director, Mr. William Kung.
Neos Therapeutics, Inc. announced that it will report its second quarter 2019 financial results prior to the opening of U.S. financial markets on Thursday, August 8, 2019.
Clinical stage cannabinoid company Botanix Pharmaceuticals Limited is pleased to announce the receipt of firm commitments in respect of a A$40m placement led by specialist US-based biotech investment funds and leading US institutional investors, as well as the appointment of two new experienced dermatology executives.
MyoKardia, Inc., announced that it will report second quarter 2019 financial and operating results on Wednesday, August 7, 2019.
Catalyst Pharmaceuticals, Inc. announced that it will release second quarter 2019 financial result after market close on Wednesday, August 7, 2019.
Proceeds will be used to grow company’s team in Lyon and Boston, to advance its current programs in hypoparathyroidism and severe insulin resistance into clinical development, and to further strengthen its product portfolio in rare endocrine and metabolic diseases
Esperion announced it will report second quarter 2019 financial results on August 8, 2019 before the U.S. financial markets open.
TLC announced financial results for the second quarter ended June 30, 2019, and provided a business update.
PRESS RELEASES